最新更新 :
19/11/2024
抗菌薬   Ceftolozane / tazobactam  
注射薬
溶媒内の安定性 混合時の安定性 安定性に影響する因子 互換性 投与経路 引用文献 PDF
   化学構造  

商品名   商品名     

商品名、賦形剤は国、製薬会社ごとに異なることがあります

Zepilen スペイン
Zerbaxa アメリカ, アルゼンチン, イギリス, エクアドル, スイス, スペイン, チリ, ドイツ, フランス, ペルー, メキシコ, ルーマニア
引用文献   注射薬   引用文献 : Ceftolozane / tazobactam  
形式 出版物
3520 実験 Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3549 実験 Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3643 実験 Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674 実験 Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3803 実験 Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics
Laboratoires Merck Sharp & Dohme Chibret 2020
3827 ポスター Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 ポスター Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 ポスター So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3984 雑誌 Meyer K, Santarossa M, Danziger L.H, Wenzler E.
Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
Hosp Pharm 2017 ,52;3 : 221-228
4055 雑誌 Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 雑誌 Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4378 雑誌 Harmanjeet H, Jani H, Zaidi S.T.R, Wanandy T, Castelino R.L, Sud K, Peterson G.M, Patel R.P.
Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions.
Perit Dial Int 2020 ; 40, 5: 470-476.
4434 雑誌 Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4528 雑誌 Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4634 雑誌 Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458
4645 雑誌 Jamieson C, Drummond F, Hill T, Ozolina L, Gilchrist M, Seaton R.A, Santillo M, Wilkinson A-S, Allwood M.C.
Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy.
JAC Antimicrob Resist 2021
4801 雑誌 Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:

  Mentions Légales